MarketPulse

cholestatic diseases

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Expands Pipeline With Multiple Clinical Catalysts Lined Up Through 2027

ProQR Therapeutics expands pipeline with lead program AX-0810 targeting H1 2026 data readout in biliary atresia, supported by three additional programs advancing through 2027.
LLYPRQRDNAHurler syndromeclinical pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline